Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fosun Pharma to buy 100 million doses of BioNTech's COVID-19 vaccine for mainland China

12/15/2020 | 10:27pm EDT
Booth of Fosun Pharma is seen at a medical instruments and equipment expo in Beijing

(Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd on Wednesday said it will buy at least 100 million doses of a COVID-19 vaccine from Germany's BioNTech SE for use in mainland China next year, if the vaccine receives approval.

The Chinese government has not announced supply deals with Western drugmakers, which instead have partnered local firms.

Fosun said it will be entitled to 60% of annual gross profit from sales of doses that it will make from imported bulk ingredients, and 65% of profit from sales of doses imported ready for use.

For the initial supply of 50 million doses, Fosun will make an advance payment to BioNTech of 250 million euros ($303.80 million) - half by Dec. 30 and the remainder after regulatory approval - the firm said in a Hong Kong stock exchange filing.

The vaccine developed by BioNTech and U.S. partner Pfizer Inc has been administered to the public in Britain and the United States, and has received emergency-use approval in several other countries.

China has granted emergency-use status to two candidate vaccines from state-backed Sinopharm and one from Sinovac Biotech Ltd. It has approved a fourth, from CanSino Biologics Inc, for military use.

Separately, Shenzhen Kangtai Biological Products Co Ltd aims to have enough capacity to produce at least 100 million doses of a vaccine candidate from British partner AstraZeneca PLC by year-end.

Late on Tuesday, Tibet Rhodiola Pharmaceutical Holding Co said it has agreed to double the supply of the Sputnik-V vaccine to its Russian home. It now aims to make enough doses for at least 40 million Russians next year.

Fosun Pharma has brought two BioNTech candidate COVID-19 vaccines into clinical trials in China and is yet to receive regulatory approval for either.

(Reporting by Roxanne Liu in Beijing and Nikhil Kurian Nainan in Bengaluru; Editing by Shri Navaratnam and Christopher Cushing)


ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.24% 8297 Delayed Quote.13.29%
BIONTECH SE 3.41% 351.81 Delayed Quote.331.56%
CANSINO BIOLOGICS INC. 10.68% 373 End-of-day quote.111.33%
PFIZER, INC. 3.91% 45.68 Delayed Quote.24.10%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 5.24% 86.71 End-of-day quote.60.60%
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. 6.52% 139.12 End-of-day quote.-20.28%
SINOPHARM GROUP CO., LTD. 2.17% 21.2 End-of-day quote.12.41%
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. 9.99% 61.53 End-of-day quote.-8.55%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
08/03SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in ..
PU
08/02SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins Regulatory Nod for $770 Millio..
MT
08/02SHANGHAI FOSUN PHARMACEUTICAL : Announcement on the approval from csrc for the p..
PU
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
More news
Financials
Sales 2021 40 184 M 6 220 M 6 220 M
Net income 2021 4 372 M 677 M 677 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 51,0x
Yield 2021 0,60%
Capitalization 208 B 32 221 M 32 271 M
EV / Sales 2021 5,58x
EV / Sales 2022 4,93x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 86,71 CNY
Average target price 57,08 CNY
Spread / Average Target -34,2%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman
Sector and Competitors